{"id":43339,"date":"2020-08-06T17:27:45","date_gmt":"2020-08-06T15:27:45","guid":{"rendered":"https:\/\/newserver.fyb.de\/casdin-capital-invests-50-million-in-dna-script-in-series-b-financing\/"},"modified":"2020-08-06T17:27:45","modified_gmt":"2020-08-06T15:27:45","slug":"casdin-capital-invests-50-million-in-dna-script-in-series-b-financing","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/casdin-capital-invests-50-million-in-dna-script-in-series-b-financing\/","title":{"rendered":"Casdin Capital invests $50 million in DNA Script in Series B financing."},"content":{"rendered":"<p>Paris\/ Munich \u2014 <strong>Casdin Capi\u00adtal<\/strong>, a New York-based invest\u00adment firm focu\u00adsed on the life scien\u00adces and health\u00adcare indus\u00adtry, was advi\u00adsed by <strong>Baker McKen\u00adzie<\/strong> in leading the over\u00adsub\u00adscri\u00adbed <strong>$50 million<\/strong> Series B fund\u00adrai\u00adsing exten\u00adsion round for DNA Script. \u2014 Other inves\u00adtors in the expan\u00added Series B finan\u00adcing round include <strong>Dana\u00adher Life Scien\u00adces, Agilent Tech\u00adno\u00adlo\u00adgies, Merck KGaA, Darm\u00adstadt, Germany, M. Ventures, LSP Life Science Part\u00adners, Bpifrance Large Venture Fund <\/strong>and<strong> Illu\u00admina Ventures<\/strong>.<\/p>\n<p>Proceeds from the expan\u00added Series B finan\u00adcing round will enable DNA Script to acce\u00adle\u00adrate the deve\u00adlo\u00adp\u00adment of its enzy\u00adma\u00adtic DNA synthe\u00adsis (EDS) plat\u00adform tech\u00adno\u00adlogy \u2014 speci\u00adfi\u00adcally to support the launch of the company\u2019s SYNTAX\u2122 DNA bench\u00adtop printer.<\/p>\n<p>\u201cWith a cross-border team of specia\u00adli\u00adzed lawy\u00aders in the field of biotech\u00adno\u00adlogy life scien\u00adces, we were able to bring the tran\u00adsac\u00adtion to a swift close toge\u00adther with our client,\u201d commen\u00adted Bert\u00adhold Hummel, lead corpo\u00adrate part\u00adner in Munich.<\/p>\n<p>Foun\u00added in 2011, Casdin Capi\u00adtal, LLC brings deep under\u00adstan\u00adding, exper\u00adtise and a long-term perspec\u00adtive to finan\u00adcing the next gene\u00adra\u00adtion of life scien\u00adces inno\u00adva\u00adtion. Casdin Capi\u00adtal specia\u00adli\u00adzes in the firm\u2019s diagno\u00adstics and mole\u00adcu\u00adlar infor\u00adma\u00adtion port\u00adfo\u00adlio and has inves\u00adted in many of the leading pioneers, inclu\u00adding but not limi\u00adted to Foun\u00adda\u00adtion Medi\u00adcine, Invi\u00adtae, Adap\u00adtive Biotech\u00adno\u00adlo\u00adgies, Flati\u00adron Health and 23andMe.<\/p>\n<p>DNA Script was foun\u00added in Paris in 2014 and is the world leader in the produc\u00adtion of de novo synthe\u00adtic nucleic acids using an enzy\u00adma\u00adtic tech\u00adno\u00adlogy. The company\u2019s goal is to acce\u00adle\u00adrate inno\u00adva\u00adtion in life scien\u00adces and tech\u00adno\u00adlogy through rapid, afforda\u00adble and high-quality DNA synthe\u00adsis. DNA Scrip\u00adt\u2019s approach takes advan\u00adtage of natu\u00adre\u2019s billi\u00adons of years of evolu\u00adtion in DNA synthe\u00adsis to enable genome-scale synthesis.<\/p>\n<p>Baker McKen\u00adzie\u2019s Corpo\u00adrate \/ M&amp;A and Life Scien\u00adces team regu\u00adlarly advi\u00adses large phar\u00admaceu\u00adti\u00adcal, finan\u00adcial inves\u00adtor and biotech compa\u00adnies on early stage dome\u00adstic and inter\u00adna\u00adtio\u00adnal health\u00adcare tran\u00adsac\u00adtions. Most recently, Baker McKen\u00adzie advi\u00adsed BioMed\u00adPart\u00adners on its EUR 10.7 million Series A equity finan\u00adcing in Tubu\u00adlis, Cure\u00adVac on its stra\u00adte\u00adgic mRNA tech\u00adno\u00adlogy colla\u00adbo\u00adra\u00adtion with GSK, LSP Life Science Part\u00adners on a USD 38.5 million Series B finan\u00adcing in DNA Script, listed 4SC AG in a capi\u00adtal increase and inter\u00adna\u00adtio\u00adnal private place\u00adment, Gala\u00adpa\u00adgos in its 10-year global rese\u00adarch and deve\u00adlo\u00adp\u00adment colla\u00adbo\u00adra\u00adtion with Gilead, MODAG in a EUR 12 million Series A finan\u00adcing, Hita\u00adchi Chemi\u00adcal Company, Tokyo, in its acqui\u00adsi\u00adtion of German apceth Biopharma, Forbion as lead inves\u00adtor in a EUR 17 mn. Series C equity finan\u00adcing of Omei\u00adcos Thera\u00adpeu\u00adtics and in a USD 54 million Series A equity finan\u00adcing of Gotham Thera\u00adpeu\u00adtics Corpo\u00adra\u00adtion, Mundi\u00adpharma in the sale of its Limburg produc\u00adtion, Cure\u00adVac AG in a colla\u00adbo\u00adra\u00adtion with Eli Lilly and Hill\u00adhouse Capi\u00adtal as co-inves\u00adtor in the EUR 50 million Series C finan\u00adcing of Hookipa Biotech.<\/p>\n<p><strong>Legal advi\u00adsor Casdin Capi\u00adtal: Baker McKenzie<\/strong><br>\n<strong>Lead Corporate\/M&amp;A:<\/strong> <strong>Bert\u00adhold Hummel, Foto (Part\u00adner, Munich)<\/strong>, Gautier Valdi\u00adgui\u00e9 (Asso\u00adciate, Paris)<br>\nOther lawy\u00aders invol\u00adved: Corporate\/M&amp;A: Matthieu Grol\u00adlemund (Part\u00adner, Paris), Mada\u00adlina-Geor\u00adgi\u00adana Asan\u00addului (Asso\u00adciate, Paris)<br>\nTax: Guil\u00adlaume Le Camus (Part\u00adner, Paris), Robin Gaulier (Senior Asso\u00adciate, Paris)<br>\nEmploy\u00adment: Jere\u00admie Paubel (Part\u00adner, Paris), Roxane Raissi (Asso\u00adciate, Paris)<\/p>\n<p><strong>About Baker McKenzie<\/strong><br>\nBaker McKen\u00adzie advi\u00adses clients to successfully deal with the chal\u00adlenges of globa\u00adliza\u00adtion. We solve complex legal problems across natio\u00adnal borders and legal fields. Our unique culture \u2014 grown over 70 years \u2014 enables our 13,000 employees to under\u00adstand local markets while opera\u00adting inter\u00adna\u00adtio\u00adnally. We use the trus\u00adting and friendly coope\u00adra\u00adtion in our inter\u00adna\u00adtio\u00adnal network for the bene\u00adfit of our clients.<\/p>\n<p>In Germany, around 200 lawy\u00aders with proven profes\u00adsio\u00adnal exper\u00adtise and inter\u00adna\u00adtio\u00adnal expe\u00adri\u00adence repre\u00adsent the inte\u00adrests of their clients at the offices in Berlin, D\u00fcssel\u00addorf, Frankfurt\/Main and Munich. As one of the leading German law firms, Baker McKen\u00adzie advi\u00adses natio\u00adnal and inter\u00adna\u00adtio\u00adnal compa\u00adnies and insti\u00adtu\u00adti\u00adons in all areas of commer\u00adcial&nbsp;law.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Paris\/ Munich \u2014 Casdin Capi\u00adtal, a New York-based invest\u00adment firm focu\u00adsed on the life scien\u00adces and health\u00adcare indus\u00adtry, was advi\u00adsed by Baker McKen\u00adzie in leading the over\u00adsub\u00adscri\u00adbed $50 million Series B fund\u00adrai\u00adsing exten\u00adsion round for DNA Script. \u2014 Other inves\u00adtors in the expan\u00added Series B finan\u00adcing round include Dana\u00adher Life Scien\u00adces, Agilent Tech\u00adno\u00adlo\u00adgies, Merck&nbsp;KGaA,&nbsp;[\u2026]<\/p>\n","protected":false},"author":2,"featured_media":35120,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1365,1366,1367,1368,1372],"tags":[],"class_list":["post-43339","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-private-equity-en","category-news-en","category-lawyers-tax-advisors-auditors-en","category-lawyers-tax-consultants-auditors","category-consultant","news-category-venture-capital-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Casdin Capital invests $50 million in DNA Script in Series B financing. - FYB Financial Yearbook<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/casdin-capital-invests-50-million-in-dna-script-in-series-b-financing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Casdin Capital invests $50 million in DNA Script in Series B financing. - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"Paris\/ Munich \u2014 Casdin Capi\u00adtal, a New York-based invest\u00adment firm focu\u00adsed on the life scien\u00adces and health\u00adcare indus\u00adtry, was advi\u00adsed by Baker McKen\u00adzie in leading the over\u00adsub\u00adscri\u00adbed $50 million Series B fund\u00adrai\u00adsing exten\u00adsion round for DNA Script. \u2014 Other inves\u00adtors in the expan\u00added Series B finan\u00adcing round include Dana\u00adher Life Scien\u00adces, Agilent Tech\u00adno\u00adlo\u00adgies, Merck KGaA, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/casdin-capital-invests-50-million-in-dna-script-in-series-b-financing\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2020-08-06T15:27:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/08\/a-hummel.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"300\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/casdin-capital-invests-50-million-in-dna-script-in-series-b-financing\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/casdin-capital-invests-50-million-in-dna-script-in-series-b-financing\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"Casdin Capital invests $50 million in DNA Script in Series B financing.\",\"datePublished\":\"2020-08-06T15:27:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/casdin-capital-invests-50-million-in-dna-script-in-series-b-financing\/\"},\"wordCount\":612,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/casdin-capital-invests-50-million-in-dna-script-in-series-b-financing\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/08\/a-hummel.jpeg\",\"articleSection\":[\"General\",\"Featured\",\"Private equity\",\"News\",\"Lawyers\/Tax-advisors\/Auditors\",\"Lawyers, tax consultants, auditors\",\"Consultant\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/casdin-capital-invests-50-million-in-dna-script-in-series-b-financing\/\",\"url\":\"https:\/\/www.fyb.de\/en\/casdin-capital-invests-50-million-in-dna-script-in-series-b-financing\/\",\"name\":\"Casdin Capital invests $50 million in DNA Script in Series B financing. - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/casdin-capital-invests-50-million-in-dna-script-in-series-b-financing\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/casdin-capital-invests-50-million-in-dna-script-in-series-b-financing\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/08\/a-hummel.jpeg\",\"datePublished\":\"2020-08-06T15:27:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/casdin-capital-invests-50-million-in-dna-script-in-series-b-financing\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/casdin-capital-invests-50-million-in-dna-script-in-series-b-financing\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/casdin-capital-invests-50-million-in-dna-script-in-series-b-financing\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/08\/a-hummel.jpeg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/08\/a-hummel.jpeg\",\"width\":300,\"height\":300},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/casdin-capital-invests-50-million-in-dna-script-in-series-b-financing\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Casdin Capital invests $50 million in DNA Script in Series B financing.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Casdin Capital invests $50 million in DNA Script in Series B financing. - FYB Financial Yearbook","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/casdin-capital-invests-50-million-in-dna-script-in-series-b-financing\/","og_locale":"en_US","og_type":"article","og_title":"Casdin Capital invests $50 million in DNA Script in Series B financing. - FYB Financial Yearbook","og_description":"Paris\/ Munich \u2014 Casdin Capi\u00adtal, a New York-based invest\u00adment firm focu\u00adsed on the life scien\u00adces and health\u00adcare indus\u00adtry, was advi\u00adsed by Baker McKen\u00adzie in leading the over\u00adsub\u00adscri\u00adbed $50 million Series B fund\u00adrai\u00adsing exten\u00adsion round for DNA Script. \u2014 Other inves\u00adtors in the expan\u00added Series B finan\u00adcing round include Dana\u00adher Life Scien\u00adces, Agilent Tech\u00adno\u00adlo\u00adgies, Merck KGaA, [&hellip;]","og_url":"https:\/\/www.fyb.de\/en\/casdin-capital-invests-50-million-in-dna-script-in-series-b-financing\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2020-08-06T15:27:45+00:00","og_image":[{"width":300,"height":300,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/08\/a-hummel.jpeg","type":"image\/jpeg"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/casdin-capital-invests-50-million-in-dna-script-in-series-b-financing\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/casdin-capital-invests-50-million-in-dna-script-in-series-b-financing\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"Casdin Capital invests $50 million in DNA Script in Series B financing.","datePublished":"2020-08-06T15:27:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/casdin-capital-invests-50-million-in-dna-script-in-series-b-financing\/"},"wordCount":612,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/casdin-capital-invests-50-million-in-dna-script-in-series-b-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/08\/a-hummel.jpeg","articleSection":["General","Featured","Private equity","News","Lawyers\/Tax-advisors\/Auditors","Lawyers, tax consultants, auditors","Consultant"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/casdin-capital-invests-50-million-in-dna-script-in-series-b-financing\/","url":"https:\/\/www.fyb.de\/en\/casdin-capital-invests-50-million-in-dna-script-in-series-b-financing\/","name":"Casdin Capital invests $50 million in DNA Script in Series B financing. - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/casdin-capital-invests-50-million-in-dna-script-in-series-b-financing\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/casdin-capital-invests-50-million-in-dna-script-in-series-b-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/08\/a-hummel.jpeg","datePublished":"2020-08-06T15:27:45+00:00","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/casdin-capital-invests-50-million-in-dna-script-in-series-b-financing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/casdin-capital-invests-50-million-in-dna-script-in-series-b-financing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/casdin-capital-invests-50-million-in-dna-script-in-series-b-financing\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/08\/a-hummel.jpeg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/08\/a-hummel.jpeg","width":300,"height":300},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/casdin-capital-invests-50-million-in-dna-script-in-series-b-financing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"Casdin Capital invests $50 million in DNA Script in Series B financing."}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/43339","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=43339"}],"version-history":[{"count":0,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/43339\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/35120"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=43339"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=43339"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=43339"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}